New York State Teachers Retirement System Has $5.40 Million Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

New York State Teachers Retirement System boosted its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 1.2% in the 4th quarter, Holdings Channel reports. The firm owned 43,847 shares of the specialty pharmaceutical company’s stock after buying an additional 529 shares during the period. New York State Teachers Retirement System’s holdings in Jazz Pharmaceuticals were worth $5,400,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in JAZZ. Bleakley Financial Group LLC bought a new stake in Jazz Pharmaceuticals during the third quarter worth $227,000. Raymond James & Associates lifted its stake in Jazz Pharmaceuticals by 13.3% during the third quarter. Raymond James & Associates now owns 53,611 shares of the specialty pharmaceutical company’s stock worth $5,973,000 after purchasing an additional 6,293 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its stake in Jazz Pharmaceuticals by 9.0% during the third quarter. Allspring Global Investments Holdings LLC now owns 19,629 shares of the specialty pharmaceutical company’s stock worth $2,187,000 after purchasing an additional 1,616 shares during the last quarter. Signaturefd LLC lifted its stake in Jazz Pharmaceuticals by 273.4% during the third quarter. Signaturefd LLC now owns 1,516 shares of the specialty pharmaceutical company’s stock worth $169,000 after purchasing an additional 1,110 shares during the last quarter. Finally, Private Advisor Group LLC lifted its stake in Jazz Pharmaceuticals by 238.6% during the third quarter. Private Advisor Group LLC now owns 7,716 shares of the specialty pharmaceutical company’s stock worth $860,000 after purchasing an additional 5,437 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors.

Insider Activity

In other news, CEO Bruce C. Cozadd sold 2,000 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $121.17, for a total value of $242,340.00. Following the completion of the sale, the chief executive officer now directly owns 427,025 shares in the company, valued at $51,742,619.25. This trade represents a 0.47 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders sold a total of 5,053 shares of company stock worth $617,442 in the last three months. Company insiders own 4.20% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on JAZZ. Needham & Company LLC restated a “buy” rating and set a $207.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. Wells Fargo & Company upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $130.00 to $170.00 in a research note on Thursday, February 13th. HC Wainwright reiterated a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. Piper Sandler reiterated an “overweight” rating and issued a $163.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $179.00 price target on shares of Jazz Pharmaceuticals in a research note on Tuesday, December 10th. One equities research analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $180.33.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ opened at $136.84 on Friday. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The stock has a 50-day moving average of $124.59 and a 200-day moving average of $117.82. The company has a market cap of $8.27 billion, a PE ratio of 19.27, a P/E/G ratio of 1.03 and a beta of 0.56. Jazz Pharmaceuticals plc has a one year low of $99.06 and a one year high of $138.27.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.